Patents Examined by Jennifer Dunston
  • Patent number: 12291732
    Abstract: Disclosed herein is a method for producing a sialylated N-glycosylated recombinant protein in periplasm of a recombinant Escherichia coli. The sialylated N-glycosylated recombinant protein is produced in the periplasm of a recombinant Escherichia coli strain W3110?nanKETA::Kan, and a sialylated oligosaccharide chain is Neu5Ac-?-2,6-Gal-?-1,4-GlcNAc-?-1,3-Gal-?-1,3-GlcNAc.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: May 6, 2025
    Assignee: Dalian University
    Inventors: Xuejun Hu, Yao Ruan, Ning Ding, Xin Fu, Jing Zhu
  • Patent number: 12281305
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PRNP RNA in a cell or animal, and in certain instances reducing the amount of PrP protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks spongiform changes in the brain, development of abnormal protein aggregates, neuronal loss, markers of neuronal loss, rapidly progressing dementia, and death. Such neurodegenerative diseases include prion diseases, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), familial Creutzfeldt-Jakob Disease (fCJD), Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, kuru, Alzheimer's disease, or Parkinson's disease.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: April 22, 2025
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui, Hien Thuy Zhao
  • Patent number: 12274756
    Abstract: In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising contacting a target cell of the subject with an effective amount of an HCN4 disrupting agent.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: April 15, 2025
    Assignee: Yale University
    Inventors: Angelique Bordey, Lawrence Hsieh, Jianbing Zhou
  • Patent number: 12275946
    Abstract: Provided are methods, compositions, recombinant DNA molecules, and kits for cloning T cell receptors (TCRs). The methods facilitate construction of TCR expression libraries from biological samples containing antigen-specific T cells, including but not limited to tumor biopsies, including frozen tumor biopsies. Peripheral T cells that were engineered with library-derived TCR genes show potent therapeutic anti-tumor effects. The method can be performed using any sample that contains T cells, and can be performed with oligoclonal populations of T cells, such as T cells that have infiltrated a tumor. Primer combinations for first strand cDNA synthesis, second strand cDNA synthesis, and for cloning a plurality of distinct TCR ? and TCR ? chains into a plurality of vectors are provided. Cells containing the vectors are provided, as are kits for use in rapid cloning of the TCR ? and TCR ? chains.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: April 15, 2025
    Assignee: Health Research, Inc.
    Inventors: Kunle Odunsi, Richard Koya, Takemasa Tsuji
  • Patent number: 12275964
    Abstract: The present disclosure provides variant type V CRISPR/Cas effector polypeptides, fusion polypeptides comprising the variant type V CRISPR/Cas effector polypeptides, and nucleic acids comprising nucleotide sequences encoding the variant polypeptides and fusion polypeptides. The present disclosure provides methods of binding, or binding and nicking, a target nucleic acid, using a variant type V CRISPR/Cas effector polypeptide of the present disclosure. The present disclosure provides methods of detecting a single-stranded DNA, using a variant type V CRISPR/Cas effector polypeptide of the present disclosure.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: April 15, 2025
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Benjamin L. Oakes, Natalia Orlova, Junjie Liu
  • Patent number: 12252694
    Abstract: Proposed is a genomic editing vector for Eubacterium callanderi for the CRISPR/Cas9 system. The genomic editing vector for Eubacterium callanderi includes a DNA sequence encoding a guide RNA (gRNA) of a cleavage target gene; a DNA sequence encoding a Cas9 protein; a Prbo promoter that is operably linked to the DNA sequence encoding a Cas9 protein; a replication starting point derived from E. coli; a replication starting point for Eubacterium callanderi; and a marker for selecting transgenic strains. It is possible to provide a genomic editing vector for Eubacterium callanderi that can be applied to Eubacterium callanderi strains that are acetogen that is suitable for syngas biorefinery, a method for editing a genome of Eubacterium callanderi strains using the same, and transgenic Eubacterium callanderi strains using the same.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: March 18, 2025
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: In Seop Chang, Ji Yeon Kim, Ji Yeong Jeong, So Young Oh, Jin Sung Jeon
  • Patent number: 12252692
    Abstract: Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas/guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and/or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.
    Type: Grant
    Filed: August 18, 2023
    Date of Patent: March 18, 2025
    Assignee: Tune Therapeutics, Inc.
    Inventors: Brian Cosgrove, Kendra Congdon, Jason Dean, Veronica Gough, Joshua B. Black, Britta Jones
  • Patent number: 12234490
    Abstract: Provided is a genome editing composition for prime editing including a prime editor protein and a prime editing guide RNA, for editing a Z-type mutation of alpha-1 antitrypsin deficiency. The composition according to an aspect includes both a pegRNA sequence capable of effectively editing the SERPINA1 gene and prime editor 2 (PE 2), and thus, may effectively deliver the prime editor to a cell, and act specifically for a target sequence of the SERPINA1 gene, enabling genome editing with high accuracy, and therefore, may be useful as a SERPINA1 gene editing platform. In addition, the composition is capable of correcting the Z-type mutation of the SERPINA1 gene, and may be used for treatment or prevention of alpha-1 antitrypsin deficiency.
    Type: Grant
    Filed: February 16, 2023
    Date of Patent: February 25, 2025
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Hyongbum Henry Kim, Minyoung Lee, Yoo Jin Chang
  • Patent number: 12215345
    Abstract: Disclosed herein are compositions of transcription activator-like effectors transcription factors and methods of using the compositions for inducing gene expression of mammalian genes.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: February 4, 2025
    Assignee: Duke University
    Inventors: Pablo Perez-Pinera, Charles A. Gersbach
  • Patent number: 12195750
    Abstract: The invention pertains to an inducible CRISPR system for controlling expression of a CRISPR complex with an inducible fusion promoter. One embodiment of the invention provides HIV LTR-minimal Drosophila hsp70 fusion promoter that can be used for inducible co-expression of gRNA and Cas9 in HIV-infected cells to target cellular cofactors such as Cyclin T1. A single introduction of such embodiment leads to sustained suppression of HIV replication in stringent, chronically infected HeLa-CD4 cell lines as well as in T-cell lines. In another embodiment, the invention further relates to enhancement of HIV suppression by incorporating cis-acting ribozymes immediately upstream of the gRNA in the inducible CRISPR system construct. The inducible fusion promoter is adaptable for other tissue- or cell-type specific expression of the inducible CRISPR system.
    Type: Grant
    Filed: March 29, 2023
    Date of Patent: January 14, 2025
    Assignee: The Florida International University Board of Trustees
    Inventors: Hoshang Jehangir Unwalla, Srinivasan Chinnapaiyan
  • Patent number: 12195493
    Abstract: Reversibly blocked nucleoside analogues and methods of using such nucleoside analogues for sequencing of nucleic acids are provided.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: January 14, 2025
    Assignees: MGI Tech Co., Ltd., BGI Shenzhen
    Inventors: Handong Li, Snezana Drmanac, Radoje Drmanac, Xun Xu, Lingling Peng, Scott Gablenz
  • Patent number: 12180468
    Abstract: Presented herein are methods and compositions for tagmentation of nucleic acids. The methods are useful for generating tagged DNA fragments that are qualitatively and quantitatively representative of the target nucleic acids in the sample from which they are generated.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: December 31, 2024
    Assignee: Illumina, Inc.
    Inventors: Christian Gloeckner, Amirali Kia, Molly He, Trina Faye Osothprarop, Frank J. Steemers, Kevin L. Gunderson, Sasan Amini, Jerome Jendrisak
  • Patent number: 12180520
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: December 31, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Patent number: 12173304
    Abstract: Novel intron fragments are provided. The intron fragments can increase gene expression to levels equal to or higher than those achieved by the full-length intron while maintaining their ability to increase gene expression even when combined with various types of promoters and splicing donors. Particularly, the intron fragments enable loading of larger transgenes when used in genetic information delivery systems whose size is limited, for example, adeno-associated viruses (AAVs) and rhabdoviruses. Therefore, the use of the intron fragments is expected to extend the range of therapeutic genes.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: December 24, 2024
    Assignee: NEURACLE GENETICS INC.
    Inventors: Hoon Young Kong, Jong-Mook Kim, Jee Yong Kim, Sunhwa Shin, Kyungwon Lee, Joo Seok Han
  • Patent number: 12152254
    Abstract: Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array or zinc finger, and a catalytic domain comprising a sequence that catalyzes hydroxylation of methylated cytosines in DNA, and methods of use thereof.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: November 26, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Morgan Maeder, James Angstman
  • Patent number: 12146135
    Abstract: The present invention relates to a method of editing a filamentous fungal genome by direct introduction of a genome editing protein molecule or complex. The method includes three modes. In the first mode, a genome editing protein molecule or complex for a target gene is directly introduced into a cell of an Aspergillus fungus, to edit a gene in the Aspergillus fungal genome. In the second mode, a genome editing protein molecule or complex for a target region in a filamentous fungal genome, and a desired DNA fragment, are directly introduced into a filamentous fungal cell, to knock-in the DNA fragment to a desired target site in the filamentous fungal genome. In the third mode, genome editing protein molecules or complexes for plural target genes are directly introduced into a filamentous fungal cell, to carry out simultaneous editing of the plural genes in the filamentous fungal genome.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: November 19, 2024
    Assignees: NATIONAL RESEARCH INSTITUTE OF BREWING, FASMAC CO., LTD.
    Inventors: Kazuhiro Iwashita, Ken Oda, Kohei Shimamoto, Yusaku Wada
  • Patent number: 12116571
    Abstract: Provided are methods, compositions, reagents, kits that are useful for detecting a specific nucleic acid region in genome with high efficiency and high sensitivity.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 15, 2024
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventor: Pei-Zhong Tang
  • Patent number: 12104207
    Abstract: Unbiased, genomewide and highly sensitive methods for detecting mutations, e.g., off-target mutations, induced by engineered nucleases.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: October 1, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Patent number: 12084675
    Abstract: Compositions and methods for using programmable DNA binding proteins to increase the efficiency and/or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: September 10, 2024
    Assignee: Sigma-Aldrich Co. LLC
    Inventor: Fuqiang Chen
  • Patent number: 12065642
    Abstract: Compositions and methods for using nucleosome interacting protein domains to increase accessibility of programmable DNA modification proteins to target chromosomal sequences, thereby increasing efficiency of targeted genome/epigenetic modification in eukaryotic cells.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: August 20, 2024
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Fuqiang Chen, Xiao Ding, Yongmei Feng, Gregory Davis